PyInvesting

Market research

600211.SHG Tibet Rhodiola Pharmaceutical Holding Co

SHG CNY Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
13B
P/E ratio
12.74
Analyst target
59.2
Dividend yield
2.1%
Beta
0.22

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Tibet Rhodiola Pharmaceutical Holding Co is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.

From a valuation standpoint, the stock is 9.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.

Tibet Rhodiola Pharmaceutical Holding Co's total revenue rose by 18.1% to $384M since the same quarter in the previous year.

Its net income has increased by 27.8% to $94M since the same quarter in the previous year.

Finally, its free cash flow grew by 1.8% to $99M since the same quarter in the previous year.

Based on the above factors, Tibet Rhodiola Pharmaceutical Holding Co gets an overall score of 4/5.